- Home
- WGRX vs NOTV Comparison
WGRX vs NOTV Comparison
Compare WGRX & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- NOTV
- Stock Information
- Founded
- WGRX 2022
- NOTV 1974
- Country
- WGRX United States
- NOTV United States
- Employees
- WGRX N/A
- NOTV N/A
- Industry
- WGRX Other Pharmaceuticals
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- NOTV Health Care
- Exchange
- WGRX Nasdaq
- NOTV Nasdaq
- Market Cap
- WGRX 140.2M
- NOTV 137.5M
- IPO Year
- WGRX 2025
- NOTV 1997
- Fundamental
- Price
- WGRX $3.29
- NOTV $1.64
- Analyst Decision
- WGRX
- NOTV Strong Buy
- Analyst Count
- WGRX 0
- NOTV 3
- Target Price
- WGRX N/A
- NOTV $5.92
- AVG Volume (30 Days)
- WGRX 219.8K
- NOTV 1.2M
- Earning Date
- WGRX 01-01-0001
- NOTV 05-09-2025
- Dividend Yield
- WGRX N/A
- NOTV N/A
- EPS Growth
- WGRX N/A
- NOTV N/A
- EPS
- WGRX N/A
- NOTV N/A
- Revenue
- WGRX $18,128,831.00
- NOTV $475,114,000.00
- Revenue This Year
- WGRX N/A
- NOTV $6.07
- Revenue Next Year
- WGRX N/A
- NOTV $5.74
- P/E Ratio
- WGRX N/A
- NOTV N/A
- Revenue Growth
- WGRX N/A
- NOTV N/A
- 52 Week Low
- WGRX $2.32
- NOTV $1.15
- 52 Week High
- WGRX $5.69
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- NOTV 38.13
- Support Level
- WGRX N/A
- NOTV $1.15
- Resistance Level
- WGRX N/A
- NOTV $1.85
- Average True Range (ATR)
- WGRX 0.00
- NOTV 0.44
- MACD
- WGRX 0.00
- NOTV -0.05
- Stochastic Oscillator
- WGRX 0.00
- NOTV 28.16
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a seamless prescription ecosystem through an integrated technology platform, wholesale distribution, and fulfillment network focused on Independent Pharmacies and Specialty Lite medications.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.